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ABSTRACT
Background :  Previous studies showed a significant 
role of Vitamin D in modulating inflammation and 
immune abnormality in SLE. The correlation between 
vitamin D supplementation and SLE disease activity 
remains controversy. Neutrophyl-Lymphocyte 
count Ratio (NLCR) as an inflammation marker was 
significantly increased in SLE patients. 
Objective : To evaluate the effect of vitamin D 
supplementation on disease activity and neutrophyl-
lypmhocyte count ratio (NLCR) in SLE patients with 
hypovitaminosis D. 
Methods : This is a pre-post test study without control
group using a consecutive sampling method. SLE patients
were enrolled from Rheumatology Clinic of Hasan 
Sadikin General Hospital from November 2013-March 
2014. Subjects received vitamin D3 2000 IU/day for 3 
months. Data was analyzed using Wilcoxon test. 
Results : We analyzed 28 subjects with 89,3% 
of vitamin D deficiency and 10,7% of vitamin D 
insufficiency, which  converted  to 25% of  vitamin D 
deficiency, 32,1% vitamin D insufficiency and 42,9% 
normal vitamin D plasma level at the end of the study. 
After supplementation, Mexican Systemic Lupus 
Erythematosus Disease Activity Index (MEX-SLEDAI) 
and NLCR was significantly decreased (median 4(3-8) to 
2(0-6) and median 2,95(1,17-7,27) to 2,28 (1,07-4,87), 
p<0,001, respectively). SLE organ involvement such 
as mucocutan, hematology and renal also high BMI 
(>23 kg/m2) were risks of hypovitaminosis D. Vitamin 
D supplementation increased mean 25(OH)D serum 
level by 164,7%, 46,7% decreased of MEX-SLEDAI, and 
24,2% decreased of NLCR (p<0,001). Nine subjects 
(32,1%) achieved remission, 19 subjects (67,9%) at 
disease persistence and no subjects experienced flare 
up after supplementation. 
Conclusion : The effects of vitamin D3 2000 IU/day 
supplementation for 3 months are reduced disease 
activity and NLCR in SLE patients with hypovitaminosis 
D. The role of NLCR as a simple inflammation marker in 
this pilot study needs further investigation.
Systemic Lupus Erythematosus (SLE) is a 
chronic systemic autoimmune disease marked 
by autoantibody tissue deposition, tissue damage 
and heterogen clinical manifestation. Prevalence 
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of SLE in the United States is 10-400 in 100.000 
people, with women to men ratio 9−14 : 1.1 
There was lack of data for prevalence of SLE in 
Indonesia. Rheumatology Clinic Hasan Sadikin 
General Hospital, Bandung in West Java recorded 
new cases of SLE between 2003-2005 were 6,4% 
from 3025 patients, which increased to 9,07% from 
4037 patients in 2011 and 11,54% from 27.496 
patients in 2012.2,3
Pathogenesis of SLE is multifactorial (genetic, 
environment and hormonal). Clinical manifestation 
of SLE developed through autoimmune 
predisposition, autoantibody formation, then 
disease exacerbation, remission, disease damage 
and comorbidity caused by chronic infl ammation. 
Two main disease domain in SLE are disease activity 
and disease damage. Disease activity represent a 
reversible manifestation of disease which is the 
important parameter of SLE treatment.4,5,6 
Vitamin D induces chemotaxis, macrophage 
phagocytosis, Treg activity, inhibits B cell 
differentiation and proliferation, and inhibits 
autoantibody production. The role of vitamin D 
in the immune system is the reversal of immune 
abnormalities in SLE. In vivo and in vitro 
studies showed benefi cial effect of vitamin D 
supplementation on SLE immune abnormalities.7-14
SLE patients are at risk for hypovitamonis D 
due to chronic steroid and hydroxychloroquine 
usage, mucocutaneous and renal involvement, 
antibody to vitamin D, sun avoidance and VDR 
gene polymorphysm.9,14-17 However, the correlation 
and overall effect of vitamin D on disease activity 
remain unclear from the available clinical data.10-
13,18-22 
Hematologic involvement has been found in 
50-70% SLE patients, which is mainly leukopenia 
(46%), consist of 75-93% lymphopenia and 47% 
netropenia.4,23 In severe disease activity, leukopenia 
and lymphopenia can be found.24
Neutrophyl-lymphocyte count ratio (NLCR) has 
been evaluated and used as infl ammatory marker 
in various diseases.25,26,27 NLCR was signifi cantly 
higher in SLE patients than normal subjects (2,52 
vs 1,64, p=0,007).24 The role of NLCR in SLE 
disease activity monitoring is unknown.
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In this study, we evaluated the effects of vitamin D 
supplementation toward disease activity and NLCR as simple 
infl ammation marker in SLE patients with hypovitaminosis D.
   
METHODS
This was a pre-post design study without control group (quasi-
experimental study) to assess the effect of 3-month vitamin D 
supplementation on disease activity and NLCR. Samples were 
collected using consecutive sampling from admissions method 
from Rheumatology Clinic, Outpatient Department Hasan 
Sadikin General Hospital, Bandung. This study was held from 
November 2013 unit March 2014. The inclusion criterias were 
fulfi lling the 2012 SLICC SLE diagnostic criteria28, age 14-
55 years old, disease activity score using Mexican-SLEDAI 
(MEX-SLEDAI) more than 2 until 9, and vitamin D serum 
level using 25(OH)D (the best indicator for vitamin D status) 
of less than 30 ng/mL. The exclusion criterias were chronic 
kidney disease stage 4-5 patients, patients with chronic liver 
disease, subjects with disease fl are, acute infection and chronic 
infl ammation other than SLE during the study, patients 
received high dose corticosteroid (equivalent to prednisone > 
30 mg/day) in the last 30 day, pregnant and breast-feeding, 
hypolipidemic and anticonvulsant consumption, subjects 
with active tuberculosis and/or on TB treatment, and history 
of vitamin D supplementation during the last 3 month was 
excluded from the study. The study was approved by the Ethical 
Committee of the Hasan Sadikin General Hospital, Bandung. 
All patients agreed to participate and signed informed consent 
at the beginning of the study.  
Vitamin D serum level was assessed by Enzyme-linked 
Immuno Sorbent Assay (ELISA) 25(OH)D serum level 
examination. Hypovitaminosis D defi ned as vitamin D 
insuffi ciency (21−29 ng/mL) or defi ciency (< 20 ng/mL).31 
SLE disease activity was measured using Mexican SLEDAI 
(MEX-SLEDAI), with scores classifi ed as follows : 0-1 for 
remission, 2-5 represented mild disease activity, 6-9 was 
moderate and more than 10 as severe disease activity. Disease 
fl are defi ned as > 3 score increment. Remission defi ned as 
more than 3 scores reductions and less than 3 scores changes 
as disease persistence. 6,29,30 NLCR was obtained from absolute 
neutrophyl count divided by absolute lymphocyte count 
attained from leukocyte differential count25-27 Chronic kidney 
disease (CKD) stage 4-5 defi ned as glomerular fi ltration rate 
< 29 ml/minute/1,73m2 for more than 3 months by Cockroft-
Gault equation.32 Previous liver disease, physical examination 
and elevated transaminase needed to assess chronic liver 
disease.33 Fitzpatrick skin type score was evaluated to classify 
skin coloration and response to sun exposure.34 The duration 
of ultraviolet exposure (minute/day) held from interview with 
study subjects. 
Subjects received 2000 IU/day vitamin D3 
(cholecalcipherol) for 3 months based on clinical data 
from previous study that showed 100% SLE patients in our 
Rheumatology clinic was vitamin D defi ciency (median 
25(OH)D serum level was 3,84 ng/mL).22 American College 
of Rheumatology (ACR) recommended 50.000 IU/week of 
vitamin D for 8 weeks, continued with 2000-4000 IU/day 
for maintenance. ACR also stated 2000 IU/day of vitamin 
D was suffi cient to achieve optimal vitamin D status (30-60 
ng/mL) in normal subjects. Vitamin D available in Indonesia 
was supplied as vitamin D3 (cholecalcipherol) 400 IU/soft 
capsule. During the study, we supplement study subjects with 
5 soft capsule/day. We monitored every patients monthly to 
evaluate symptoms, SLE disease activity, compliance and 
any side effects to vitamin D supplementation. After 3-month 
supplementation (vitamin D serum level is not recommended 
to be remeasured for less than 3 months)31,35, we repeated 
the measurement of 25(OH)D serum level and NLCR. Data 
analysis started with Shapiro-Wilk normality test (n<50) for 
quantitative data. The comparison of MEX-SLEDAI and 
NLCR at baseline and after supplementation were analyzed 
using paired T-test or Wilcoxon’s test as appropriate using 
SPSS for window ver 17.
RESULTS
We enrolled 33 eligible SLE patients. During this study, 1 
subject reported skin rash, 2 subjects with nausea-vomiting 
and 2 subjects were excluded due to uncompliance to 
supplementation. At the end of the study, 28 subjects available 
to be analyzed. Table 1 showed that the prevalence of SLE 
among the study subjects was higher in women (92,9%). 
Mean age was 30,7+10,5 years old. Median disease duration 
was 21,25 months (4 -156 months). Median Body Mass Index 
(BMI) was 21,25 kg/m2 (16,1 - 41,1 kg/m2). Frequency of 
SLE manifestation consisted of 92,9% mucocutaneous, 25% 
muskuloskeletal, 67,9% hematology, 57,1% renal, 17,9% 
vaskulitis, 21,4% neuropsychiatric (NPSLE) and 14,3% 
serositis. Baseline Median (25(OH)D) serum level was 
9,24 ng/mL (3-24,64 ng/mL). All subjects (100%) received 
methylprednisolone. Other SLE medications were chloroquine 
(57,1%), cyclophosphamide (14,3%), azathioprine (39,3%) 
and cyclosporine (3,5%). Only age (p=0,261) and vitamin D 
level after supplementation (p=0,170) were distributed normal 
(p>0,05). Baseline median MEX-SLEDAI score and NLCR 
were 4 (3 – 8) and 2,95 (1,17 - 7,27) (Table 2).
Table 1. Baseline characteristics of patients (n=28)
Characteristics n = 28 
Sex (n, %)  
Male 2 (7,1%)
Female 26 (92,9%)
Age (years)
Mean ± SD 30,7 ± 10,5
SLE disease duration(months)
Median (Range) 30,5 (4-156)
Body Mass Index / BMI (kg/m2)
Median (Range) 21,3 (16,1-41,1)
SLE manifestation (n,%)
Mucocutan 26 (92,9%)
Musculoskeletal 7 (25%)
Hematology 19 (67,9%)
Renal 16 (57,1%)
Vaskulitis 5 (17,9%)
NPSLE 6 (21,4%)
Serositis 4 (14,3%)
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SLE medications (n, %)
Corticosteroid 28 (100%)
Chloroquine 16 (57,1%)
Azathioprine 11 (39,3%)
Cyclophosphamide 4 (14,3%)
Cyclosporine 1 (3,6%)
UV exposure (minute/day)
Median (Range) 15 (5-60)
Skin colour (n %) (Fitzpatrick skin type 
score)
2 5 (17,9%)
3 11 (39,3%)
4 7 (25%)
5 4 (17,9%)
Sunblock application SPF 30 (n, %)
Applying 19 (67,9%)
Not applying 9 (32,1%)
Vit D Compliance (%)
Median (Range) 96,7 (90-100)
Baseline 25(OH)D serum level (ng/mL)(n,%)
Insufficiency (20-29)        3 (10,7 %)
Deficiency (<20) 
Severe Deficiency (<12) 
      25 (89,3 %)
           19 (67,9%)
     
The effects of vitamin D supplementation on MEX-SLEDAI and 
NLCR
Table 2 showed 3-month vitamin D supplementation resulted 
in statistically signifi cance decreased disease activity (p<0,05). 
There was 46,7% decrease in MEX-SLEDAI, 24,2% decrease 
in NLCR, simultaneously with 164,7% increase in mean 
25(OH)D serum level after supplementation.    
Table 2. Vitamin D (25(OH)D) serum level, MEX-
SLEDAI dan NLCR  
Pre and post
Variables
Before 
cholecalci-
pherol
supplemen-
tation
After  
cholecalci-
pherol
supple-
mentation
pre&post
changes
p-value*
(pre) (post)
MEX-SLEDAI     
Median 
(Range) 4 (3-8) 2 (0-6)
46,7%
Decrease 
0,000
NLCR
Median 
(Range)
2,95 (1,17-
7,27)
2,28 (1,07-
4,87)
24,2%
Decrease 
0,000
25(OH)D (ng/mL)
Mean ± SD 10,2 ± 5,8 27 ± 12,1 164,7%
Increase
0,000
Note * : p-value submitted from Wilcoxon test, p < 0,05 as level 
of significance.
Figure 1. MEX-SLEDAI, NLCR and 25(OH)D serum level pre and post.
 The effect of vitamin D supplementation (along with SLE 
immunosupresive therapy) on disease activity comprised of 
32,1% subjects with disease remission, 67,9% experienced 
persistence and no subject with disease fl are during 
observation. (Table 3)
Table 3. MEX-SLEDAI after cholecalcipherol supplementation 
MEX-SLEDAI 
decreasing >3
(remission)
(n,%)
MEX-SLEDAI 
decreasing <3
(persistent)
(n,%)
MEX-SLEDAI 
increasing > 3
(flare up)
(n,%)
9 (32,1%) 19 (67,9%) -
TOTAL 28 (100%)
    
There were 89,3% subjects with vitamin D defi ciency at 
baseline. After 3-month cholecalcipherol supplementation, 
25% subjects remains defi ciency but 42,9% subjects achieved 
optimal vitamin D serum level. (Table 4)
Table 4. Characteristics of 25(OH)D serum level pre and post
Before cholecal-
cipherol
supplementation
After cholecalci-
pherol
supplementation
(pre)
n=28
(post)
n=28
25(OH)D serum level (ng/mL)
Normal  (30-60) - 12(42,9%)
Insufficiency  (20-29)
Deficiency  (<20)
Severe deficiency (<12)
3(10,7%)
25 (89,3%)
19 (67,8%)
9 (32,1%)
7 (25%)
5 (17,8%)
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DISCUSSION
This is a pre-post design study without control group (quasi-
experimental study) to assess the effect of 3-month vitamin 
D supplementation on disease activity and NLCR in SLE 
Patients. This study design was selected because we found 
limitation in obtaining placebo or control group as comparison. 
On the fi rst month follw-up, one subject reported skin rash, 
which is concluded as hypersensitivity reaction (co-evaluation 
with Dermatovenereologist). Moreover, two subjects reported 
gastrointestinal intolerance (nausea and vomitting). On the 
second month, two other subjects reported compliance less 
than 90%. Those fi ve subjects’ participation were discontinued 
from our study. 
At the end of the study, we analyzed 28 subjects with women 
subjects in majority (92,9%), and mean age of 30,7+10,5 years 
old, which is in line with the epidemiology of SLE.2 Baseline 
data showed mucocutaneous (92,9%), hematology (67,9%) 
and renal (57,1%) manifestation of SLE because vitamin D 
metabolism involves skin and kidney.31 Also Bogaczewicz J 
et al12 found that SLE patients with hematologic (leukopeni) 
and renal involvement had higher risk of vitamin D defi ciency. 
Fifty percent subjects had BMI>23 kg/m2 (overweight) which 
increased the risk of hypovitaminosis D as vitamin D was 
sequestrated in the adipose tissue.31 Table 1 showed 100% 
subjects had corticosteroid, 39,3% subjects with Fitzpatrick 
skin type 3 and  67,9% applied sunscreen that also increased 
the risk of hypovitaminosis D. 9,14-17  
Initially, 89,3% subjects were vitamin D defi ciency 
(25(OH)D <20ng/mL) and convert to 25% subjects after 
3-month supplementation (table 4). We observed 42,9% 
subjects with normal vitamin D status, but 32,1% still in 
insuffi ciency after supplementation. Five subjects (17,8%) 
persist as severe vitamin D defi ency (<12 ng/mL) due to 
less compliance, high BMI and gastrointestinal symptoms 
during the study. Robinson AB et al found that 400 IU per day 
vitamin D supplementation will increase mean 25(OH)D, but 
few subjects still hypovitaminosis D yet recommend higher 
dose of vitamin D, especially for patients with proteinuria and 
high disease activity.8 
Table 2 demonstrate 46,7% decrease mean MEX-SLEDAI 
(p <0,001) and table 3 showed no subjects suffered fl are up 
during study. According to a metaanalysis by Sakthiswary 
R et al18, theres is a strong association between level of 
vitamin D and disease activity and no association with 
disease damage. Kurniati et al reported vitamin D 2000 IU/
day followed by signifi cant MEX-SLEDAI score decrease 
(6,85+2,71 vs 3,98+3,53, p<0,005) without marked difference 
of 1,25(OH)2D3 serum level.
20 Handono et al21 also reported 
negative correlation between 25(OH)D serum level and disease 
activity (r=-0,659, p=0,000). Altogether with Abou-Raya et 
al13,Borba et al19 and Petri et al36 whose reported signifi cantly 
better infl ammation marker after vitamin D3 supplementation, 
vitamin D3 2000 IU/day could be considered as “additional” 
therapy for SLE.
High risk hypovitaminosis D patients (such as overweight, 
darker skin colour, sun avoidance, sun screen application, 
mucocutaneous, hematologic and renal involvement and 
drugs) should be considered for early vitamin D status 
examination, higher vitamin D supplementation and frequent 
monitoring of vitamin D serum level.35  
We observed 24,2% decrease median NLCR, from 
2,95 (1,17-7,27) to 2,28 (1,07-4,87) p<0,001). Dan JQ dkk 
reported decrease NLCR afte Radio Frequency Ablation in 
178 hepatocelullar carcinoma patients, which indicate better 
survival.37 Wolfsminke et al observed that NLCR was not 
a useful predictive value in 440 severe malaria patients.38 
Oehadian et al reported signifi cantly higher NLCR in SLE 
patients compared to normal (2,52 vs 1,64, p=0,007). Cut-off 
NLCR of > 1,93 resulted in 70% sensitivity and 67% specifi ty 
to differentiate SLE and normal subjects.24 Though our study 
result is consistent with Oehadian et al, but the role NLCR 
as a simple infl ammation marker useful for disease activity 
monitoring in SLE still need further investigation.   
Few subjects reported fatigue as part of baseline MEX-
SLEDAI assessment (data not shown). Sterling et al reported 
fatigue as frequently undiagnosed disease burden but 
infl uenced the quality of life of SLE patients.39 We observed 
that after vitamin D3 2000 IU/day for 3 months, those subjects 
reported less fatigue and one subjects can back to work 
(through patient interview).     
Our study limitation were no placebo or control group 
and relatively short duration of study. We expected more 
apparent vitamin D effect on disease activity and NLCR in 
longer supplementation duration. Polymorphism of vitamin D 
receptor needed to investigated for 17,8% subjects persist in 
severe vitamin D defi ciency.  
CONCLUSION
In the present study, there was a signifi cant reduced disease 
activity and NLCR in SLE patients with hypovitaminosis D 
after the administration of vitamin D along with the main 
immunosuppresive SLE therapy. The role of NLCR as a simple 
infl ammation marker in SLE disease activity monitoring needs 
to be further investigated. Furthemore, fatigue evaluation in 
SLE patients with objective measurement and the correlation 
with vitamin D supplementation also need further research. 
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